Ameriprise
ADMA icon

Ameriprise’s ADMA Biologics ADMA Stock Holding History

Ameriprise’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.53M Sell
421,429
-44,173
-9% -$403K ﹤0.01% 2788
2026
Q1 		$4.2M Sell
465,602
-86,394
-16% -$1.36M ﹤0.01% 2548
2025
Q4 		$10.1M Buy
551,996
+30,125
+6% +$508K ﹤0.01% 1899
2025
Q3 		$7.65M Sell
521,871
-95,223
-15% -$1.63M ﹤0.01% 2109
2025
Q2 		$11.2M Sell
617,094
-56,049
-8% -$1.14M ﹤0.01% 1725
2025
Q1 		$13.4M Sell
673,143
-42,529
-6% -$736K ﹤0.01% 1563
2024
Q4 		$12.3M Buy
715,672
+88,542
+14% +$1.67M ﹤0.01% 1651
2024
Q3 		$12.5M Buy
627,130
+504,357
+411% +$7.84M ﹤0.01% 1623
2024
Q2 		$1.37M Sell
122,773
-96,765
-44% -$812K ﹤0.01% 3024
2024
Q1 		$1.45M Sell
219,538
-128,870
-37% -$704K ﹤0.01% 3020
2023
Q4 		$1.57M Sell
348,408
-70,932
-17% -$262K ﹤0.01% 2992
2023
Q3 		$1.5M Buy
419,340
+16,634
+4% +$64K ﹤0.01% 2962
2023
Q2 		$1.49M Buy
402,706
+32,844
+9% +$122K ﹤0.01% 3018
2023
Q1 		$1.22M Sell
369,862
-370
-0.1% -$1.28K ﹤0.01% 3067
2022
Q4 		$1.44M Sell
370,232
-3,924
-1% -$12.1K ﹤0.01% 2955
2022
Q3 		$910K Sell
374,156
-11,417
-3% -$27.4K ﹤0.01% 3156
2022
Q2 		$764K Buy
+385,573
New +$759K ﹤0.01% 3227
2021
Q1 		– Sell
-21,400
Closed -$44K – 3831
2020
Q4 		$44K Sell
21,400
-27,280
-56% -$57.3K ﹤0.01% 3729
2020
Q3 		$116K Buy
48,680
+2,270
+5% +$6.22K ﹤0.01% 3625
2020
Q2 		$136K Buy
46,410
+14,110
+44% +$40.5K ﹤0.01% 3551
2020
Q1 		$93K Buy
32,300
+8,700
+37% +$30.1K ﹤0.01% 3541
2019
Q4 		$94K Sell
23,600
-22,405
-49% -$97.7K ﹤0.01% 3645
2019
Q3 		$205K Sell
46,005
-3,395
-7% -$14.2K ﹤0.01% 3548
2019
Q2 		$191K Buy
+49,400
New +$218K ﹤0.01% 3593

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Ameriprise's ADMA Position: Q2 2026 in Review

Ameriprise reduced its ADMA Biologics (ADMA) stake by 9.5% in Q2 2026, selling an estimated $403K and leaving 421,429 shares worth $3.53M. The position accounts for ﹤0.01% of the portfolio, ranked #2788.

Ameriprise first reported a position in ADMA in Q2 2019 and has held it in 24 quarters since. The position peaked at $13.4M in Q1 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Ameriprise held 421,429 shares of ADMA Biologics worth $3.53M as of Q2 2026.
  • Ameriprise sold 44,173 ADMA Biologics shares in Q2 2026, an estimated $403K.
  • ADMA Biologics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #2788 holding.
  • Ameriprise first reported a position in ADMA Biologics in Q2 2019 and has held it in 24 quarters since.
  • Ameriprise's ADMA Biologics position peaked at $13.4M in Q1 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.